# OnCo record bipolar-androgen-therapy (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/bipolar-androgen-therapy/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "bipolar-androgen-therapy" ;
  schema:name "Bipolar androgen therapy (BAT)"@en ;
  schema:alternateName "BAT"@en, "bipolar androgen therapy"@en, "supraphysiological testosterone"@en, "high-dose testosterone therapy"@en, "testosterone cycling prostate cancer"@en ;
  schema:description "Deliberately giving large doses of testosterone to men whose prostate cancer has learned to live without it, swinging the level from very high to very low each month. It is the opposite of standard treatment, and about a third of men respond, with about half then responding again to the hormone-blocking drug that had stopped working."@en ;
  schema:url <https://onco.cc/terms/bipolar-androgen-therapy/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s1470-2045(17)30906-3>, <https://doi.org/10.1200/jco.20.02759> ;
  onco:tag "gu", "prostate-glossary" ;
  onco:related <https://onco.cc/key-papers/paper-teply-restore-bipolar-androgen-therapy-lancet-oncol-2018/>, <https://onco.cc/key-papers/paper-denmeade-transformer-bipolar-androgen-therapy-jco-2021/>, <https://onco.cc/ideas/idea-prostate-bipolar-androgen-therapy-phase-3-on-pfs2/>, <https://onco.cc/terms/intermittent-androgen-deprivation/>, <https://onco.cc/ideas/idea-bio1-alternating-schedules/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:sections <https://onco.cc/fronts/hormonal/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/> ;
  onco:drugs <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/abiraterone/> ;
  onco:institutions <https://onco.cc/institutions/johns-hopkins/> ;
  onco:terms <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/adt/>, <https://onco.cc/terms/psa50/>, <https://onco.cc/terms/androgen-deprivation-therapy/>, <https://onco.cc/terms/quality-of-life/>, <https://onco.cc/terms/intermittent-androgen-deprivation/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-generic-repurposing/>, <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-trial-design/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-teply-restore-bipolar-androgen-therapy-lancet-oncol-2018/>, <https://onco.cc/key-papers/paper-denmeade-transformer-bipolar-androgen-therapy-jco-2021/>, <https://onco.cc/key-papers/paper-chen-androgen-receptor-overexpression-antiandrogen-resistance-nat-med-2004/> .